Ashraf Dwal, MD
Nephrology · Gulfport, MSNPI 1689088403
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $311 and has fallen 58.4% since, to $129 in 2025. That places this record below the midpoint for nephrology clinicians in MS, where the typical reported total is $1,460.
Across 42 payments — averaging $23.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$146
- Novartis$125
- Aurinia Pharma U.S., Inc.$114
- Mallinckrodt Hospital Products Inc.$86
- Johnson & Johnson$78
- Pfizer$73
- plus $359 from 9 others
What the payments were for
- Food & beverage$977100%
- Education$30%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 2 | $146 |
| Novartis | 4 | $125 |
| Aurinia Pharma U.S., Inc. | 2 | $114 |
| Mallinckrodt Hospital Products Inc. | 4 | $86 |
| Johnson & Johnson | 5 | $78 |
| Pfizer | 4 | $73 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $64 |
| AstraZeneca | 3 | $63 |
| E.r. Squibb & Sons, L.L.C. | 3 | $53 |
| OPKO Pharmaceuticals, LLC | 3 | $46 |
| Akebia Therapeutics Inc | 2 | $40 |
| AbbVie | 1 | $29 |
| Travere Therapeutics, Inc. | 3 | $25 |
| Amgen | 1 | $22 |
| Calliditas Therapeutics US Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JYNARQUE$122
How this compares
$980 in reported general payments places this provider in the 40th percentile of 105 nephrology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nifedipine ErNifedipine | 16 | $325 |
| Hydralazine Hcl | 24 | $188 |
| Losartan Potassium | 11 | $77 |
| Lisinopril | 24 | $75 |
| Amlodipine Besylate | 21 | $69 |
| Furosemide | 14 | $27 |
| Hydrochlorothiazide | 12 | $3 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Gulfport
- Jedd SeigermanGulfport$5K
- Biju MarathGulfport$3K
- Douglas LanierGulfport$3K
- Erica HopkinsGulfport$2K
- Joseph OgormanGulfport$2K
- Amery CreightonGulfport$2K
- Mohit AhujaFlowood$427K
- Padam HirachanNatchez$29K
- Brian RifkinHattiesburg$23K
- Otis GowdyMeridian$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.